Jonathan Smith, Author at Labiotech.eu

About

Reporter for Labiotech. I hail from the UK. I was born in Bristol, studied Neuroscience in the University of Bristol, and trained mice in Eisai, Hertfordshire, for one year. I then tickled locusts for my Ph.D. at the University of Leicester, before eventually ending up here!
Out of the office, I travel, play video games and board games, drink beer and play the piano.

Articles by Jonathan Smith

News and Trends 8 Jun 2022

The top European biotech investments in May 2022

Biotech investments in Europe jumped in May 2022 with a large initial public offering from the US/UK firm PepGen. Meanwhile, oncology companies Tubulis, Domain Therapeutics, and EngImmune Therapeutics topped the private biotech investment rounds. Public stock markets remain in a volatile state for biotech companies, with a lot of uncertainty remaining over widespread inflation. Against […]

June 8, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 24 May 2022

Vaccines mobilized to control monkeypox outbreak

An unusual outbreak of monkeypox is causing concern worldwide in the shadow of the destructive Covid-19 pandemic. Both old and emerging vaccine technology could aid the fight against the outbreak. In the wake of the world-changing Covid-19 pandemic, the World Health Organization (WHO) is voicing alarm over another unusual outbreak, this time of the viral […]

May 24, 2022 - 5 minutesmins - By Jonathan Smith

glucagon zealand pharma diabetes insulin immunotherapy

News and Trends 20 May 2022

Zealand Pharma’s drug for rare metabolic disease smashes phase III

After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III trial. In late 2020, the Danish firm Zealand Pharma A/S hit a big obstacle when its peptide drug dasiglucagon failed to treat the […]

May 20, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 16 May 2022

Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags

The stock price of the French Covid-19 vaccine maker Valneva has been knocked down by 20% as the company faces losing a supply contract with the European Commission. Despite receiving a glowing marketing authorization from the UK’s drug regulator in April this year, Valneva is struggling to gain traction with its Covid-19 vaccine in the […]

May 16, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 12 May 2022

The Top European Biotech Investments in April 2022

Private biotech investments in Europe were on a steady decline in April 2022 as biotech public markets continued to disappoint. The top funding rounds were dominated by UK and Swiss firms targeting genetic diseases and cancer. April 2022 provided no relief for the European biotech industry as public stock markets remain anemic. Though flush with […]

May 12, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 10 May 2022

eureKARE Launches €150M Merger to Form Cell and Gene Therapy CDMO

The French startup creator eureKARE has set up a special purposes acquisition company (SPAC) with the ambition to merge multiple European contract development and manufacturing organizations into a heavyweight serving developers of gene therapies, protein drugs, and microbiome therapeutics. Over the last few years, record levels of funding have flowed into the biotech industry, particularly […]

May 10, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 5 May 2022

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […]

May 5, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 3 May 2022

Tubulis Rides Investment Wave in ADCs with €60M Series B

The German firm Tubulis has raised a €60M Series B round to advance cancer drugs called antibody-drug conjugates (ADCs) to clinical trials. This takes place as the ADC space is heating up with rapid approvals and investment deals. ADCs are the product of attempts to make more selective, safer versions of traditional chemotherapy. They consist […]

May 3, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 29 Apr 2022

Denmark Recruits Lifebit to Boost Personalized Medicine with Genomics

The Danish National Genome Center has teamed up with the UK firm Lifebit to improve the access and sharing of genomic data as the nation moves towards the adoption of personalized medicine. Personalized medicine is capturing the attention of healthcare authorities across the world. By harvesting genome sequences from patient populations, researchers can mine vast […]

April 29, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 28 Apr 2022

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets, including one that sank Quench Bio last year. In 2020, Quench Bio captured the imagination of investors with the US firm’s ambition to develop a new class of anti-inflammatory drugs. The […]

April 28, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 27 Apr 2022

Cancer Research UK Deploys €700M to Foster Oncology Startups

In a show of strength after an income squeeze during the Covid-19 pandemic, the charity Cancer Research UK has dedicated €711M (£600M) to setting up a new innovation arm and seed fund designed to speed up the commercialization of oncology innovation. For decades, Cancer Research UK (CRUK) has played a pivotal role in nurturing advances […]

April 27, 2022 - 4 minutesmins - By Jonathan Smith

cardiovascular disease heart attack forcefield therapeutics

News and Trends 25 Apr 2022

Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs

The startup Forcefield Therapeutics has been unveiled in the UK with €6M (£5.5M) backing from the investment firm Syncona. The mission is to develop the first drugs to safeguard heart muscle from damage during heart attacks. A sudden heart attack, also known as acute myocardial infarction, happens when the flow of blood to the heart […]

April 25, 2022 - 4 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Jonathan Smith

About

Articles by Jonathan Smith

The top European biotech investments in May 2022

Vaccines mobilized to control monkeypox outbreak

Zealand Pharma’s drug for rare metabolic disease smashes phase III

Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags

The Top European Biotech Investments in April 2022

eureKARE Launches €150M Merger to Form Cell and Gene Therapy CDMO

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Tubulis Rides Investment Wave in ADCs with €60M Series B

Denmark Recruits Lifebit to Boost Personalized Medicine with Genomics

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

Cancer Research UK Deploys €700M to Foster Oncology Startups

Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Jonathan Smith

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!